Piper Jaffray Companies reissued their buy rating on shares of CymaBay Therapeutics (NASDAQ:CBAY) in a research report released on Friday. Piper Jaffray Companies currently has a $16.00 price target on the biopharmaceutical company’s stock.
Several other research analysts also recently commented on CBAY. HC Wainwright reaffirmed a buy rating and set a $12.00 target price on shares of CymaBay Therapeutics in a report on Tuesday, November 28th. Leerink Swann reaffirmed a buy rating and set a $16.00 target price on shares of CymaBay Therapeutics in a report on Tuesday, November 28th. Oppenheimer set a $15.00 target price on CymaBay Therapeutics and gave the stock a buy rating in a report on Wednesday, January 10th. Zacks Investment Research downgraded CymaBay Therapeutics from a hold rating to a sell rating in a report on Tuesday, January 16th. Finally, Roth Capital reaffirmed a buy rating and set a $27.00 target price on shares of CymaBay Therapeutics in a report on Thursday, January 25th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $17.78.
CymaBay Therapeutics (NASDAQ:CBAY) traded up $1.25 during midday trading on Friday, hitting $13.74. The company had a trading volume of 1,730,222 shares, compared to its average volume of 877,939. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.39 and a current ratio of 7.39. CymaBay Therapeutics has a 12 month low of $3.16 and a 12 month high of $15.59. The firm has a market cap of $730.69, a P/E ratio of -16.55 and a beta of 1.96.
CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings data on Thursday, March 15th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.06. The firm had revenue of $5.20 million for the quarter, compared to analyst estimates of $1.25 million. equities research analysts anticipate that CymaBay Therapeutics will post -0.86 EPS for the current year.
In other news, Director Kurt Von Emster sold 4,300 shares of CymaBay Therapeutics stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $10.21, for a total value of $43,903.00. Following the completion of the transaction, the director now directly owns 90,000 shares of the company’s stock, valued at approximately $918,900. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last three months, insiders sold 978,140 shares of company stock valued at $11,761,941. Corporate insiders own 15.10% of the company’s stock.
Several hedge funds have recently bought and sold shares of CBAY. Perceptive Advisors LLC bought a new position in shares of CymaBay Therapeutics in the 3rd quarter worth about $18,948,000. Farallon Capital Management LLC bought a new position in shares of CymaBay Therapeutics in the 4th quarter worth about $10,120,000. Citadel Advisors LLC bought a new position in shares of CymaBay Therapeutics in the 3rd quarter worth about $5,159,000. EAM Investors LLC bought a new position in shares of CymaBay Therapeutics in the 3rd quarter worth about $4,788,000. Finally, UBS Asset Management Americas Inc. bought a new position in shares of CymaBay Therapeutics in the 4th quarter worth about $5,423,000. 61.36% of the stock is owned by hedge funds and other institutional investors.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.